News

Sell Dr Lal Pathlabs Ltd For Target Rs. 2,600 By Yes Securities Ltd In line quarter; volume growth still lackluster Result Synopsis Dr Lal reported largely in line quarter as sample growth yet again outpaced volume expansion. Swasthfit share continues to rise YoY which is driving large part of realization improvement. Margin strength is consistently evident even as management alluded to higher opex in H2 leading to lower projected margin for the second half. With no visible price hike in FY25, expect bulk of the per patient realization to come from mix ...
Sell Dr Lal Pathlabs Ltd For Target Rs. 2,600 By Yes Securities Ltd
Sell Dr Lal Pathlabs Ltd For Target Rs. 2,600 By Yes Securities Ltd
Source: Yes Securities Ltd
2024-11-01 12:51:41 pm
Buy Dr Lal Pathlabs Ltd For Target Rs. 3,400 By Emkay Global Financial Services Margins surprise on the back of Suburban and Swasthfit DLPL’s Q2FY25 margins expanded by 110bps YoY on the back of improving contribution from Swasthfit and better margin performance at Suburban (~600bps QoQ). Sample volume growth (+8.6% YoY), however, remained soft owing to lower incidence of monsoon-related illnesses (except West region) and a higher base. With the management’s target of adding 15-20 labs in FY25, signs of Suburban turning around, and predatory pricing recedi...
Buy Dr Lal Pathlabs Ltd For Target Rs. 3,400 By Emkay Global Financial Services
Buy Dr Lal Pathlabs Ltd For Target Rs. 3,400 By Emkay Global Financial Services
Source: Emkay Global Financial Services
2024-11-01 10:23:09 am
India`s Dr Lal Path Labs posts bigger-than-expected Q2 profit on demand for medical tests Dr. Lal PathLabs, India's top diagnostics firm by revenue, reported a bigger-than-expected second-quarter profit on Wednesday, driven by continued demand and a rising awareness for health and wellness. The company's consolidated net profit increased 18% year-over-year to 1.29 billion rupees ($15.4 million), increasing for the sixth quarter in a row. That beat analysts' estimates of 1.26 billion rupees, according to estimates compiled by LSEG. The company, which operates a...
India`s Dr Lal Path Labs posts bigger-than-expected Q2 profit on demand for medical tests
India`s Dr Lal Path Labs posts bigger-than-expected Q2 profit on demand for medical tests
Source: Reuters
2024-10-23 05:06:36 pm
Sell Dr Lal Pathlabs Ltd For Target Rs.2,550 By Yes Securities Lack of volume traction keeps us away Result Synopsis Dr Lal delivered no surprises in volume growth or revenues in Q1 and rather we reckon patient footfall growth at 5.5% was again underwhelming while test volume was up 9% YoY. With ever increasing Swasthfit share to 25% (vs 22% YoY) and rising 150bps every year, some of the repeat patient volume in the discretionary bucket would be upsold the wellness program. This could be pulling down the overall footfall growth though patient volum...
Sell Dr Lal Pathlabs Ltd For Target Rs.2,550 By Yes Securities
Sell Dr Lal Pathlabs Ltd For Target Rs.2,550 By Yes Securities
Source: Yes Securities Ltd
2024-08-10 12:09:02 pm
India's Dr Lal PathLabs tops Q1 profit estimates on strong testing demand  Dr. Lal PathLabs reported first-quarter profit above expectations on Wednesday on strong demand for its medical tests in smaller cities and towns amidst rising awareness for health and wellness in India. Shares of the diagnostic firm rose as much as 6% to hit the day's highest, before closing up 3.4%. Consolidated net profit rose 28% to 1.06 billion rupees (around $13 million) for the quarter ended June 30, beating analysts' estimate of 992.7 million rupees, per LSEG. &...
India's Dr Lal PathLabs tops Q1 profit estimates on strong testing demand
India's Dr Lal PathLabs tops Q1 profit estimates on strong testing demand
Source: Reuters
2024-08-07 04:58:45 pm
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,800 By Emkay Global Financial Services Swasthfit drives the beat DLPL posted a robust quarter, with revenue growing 11% YoY on the back of sample volume increasing 9% YoY and Swasthfit contributing 24% to the topline. DLPL’s focus and execution prowess on expanding its presence in Tier 3+ cities (bulk of expansion) is likely to support its high single-digit revenue growth in core markets (Delhi NCR). With pricing pressures abating, DLPL remains well positioned to capture the structural tailwinds enjoyed by the Indian heal...
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,800 By Emkay Global Financial Services
Buy Dr Lal Pathlabs Ltd For Target Rs. 2,800 By Emkay Global Financial Services
Source: Emkay Global Financial Services
2024-07-02 11:30:34 am
BUY Dr Lal Pathlabs Ltd. For Target Rs. 2,735 - JM Financial Services Staging a comeback DLPL’s management commentary struck a bullish tone, anticipating double digit growth in FY25 (likely ~12% in our view) driven by improved volumes and a favourable case mix. The key positive readout here is – DLPL will not take price hikes to achieve this! The company delivered a strong performance (5% PAT beat on cons.) as well. A large part of the current 11% growth was driven by Tier 3+ growth, higher Swasthfit and price hikes. Volume growth was admittedly ...
BUY Dr Lal Pathlabs Ltd. For Target Rs. 2,735 - JM Financial Services
BUY Dr Lal Pathlabs Ltd. For Target Rs. 2,735 - JM Financial Services
Source: JM Financial Services
2024-06-30 05:41:06 pm
REDUCE Dr Lal Pathlabs Ltd. For Target Rs.2,550 - Yes Securities Subdued volume outlook Result Synopsis Dr Lal guided to better FY25 growth than FY24 less the contribution from price hike (~3.5%). Implied volume growth appears to be around 6-7% based on guidance coupled with mix change that would drive hitherto unchanged early double digit growth expectation – only difference being we have cut FY25/26 volume estimate by 4-5% given the weak prognosis and bumped up realization/patient to capture the upside from mix change. Company to reinvest in...
REDUCE Dr Lal Pathlabs Ltd. For Target Rs.2,550 - Yes Securities
REDUCE Dr Lal Pathlabs Ltd. For Target Rs.2,550 - Yes Securities
Source: Yes Securities Ltd.
2024-06-26 03:30:35 pm
India`s Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests Dr. Lal PathLabs, India's biggest diagnostics firm by revenue, posted a higher profit for the third straight quarter on Thursday, due to more diagnostics and tests in the monsoon and winter seasons as well as an increase in COVID cases. The company's consolidated net profit jumped 54% year-over-year to 813 million rupees (nearly $10 million) in the third quarter. Its total revenue climbed by 10% to 5.39 billion rupees The October-December quarter encompasses the tail end of t...
India`s Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests
India`s Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests
Source: Reuters
2024-02-01 03:08:14 pm
Reduce Dr Lal Pathlabs Ltd For Target Rs.2,500 - Yes Securities Worst of volume weakness over; lack of recovery keeps us away Result Synopsis Volume growth remained subdued at 4% YoY on reported basis and ~8% YoY net of RT PCR tests. Price hikes and cost control led to a strong margin beat; albeit reckon management focus is firmly on driving topline growth from volumes rather than being fixated on margin. Gradual expansion in Tier 3 & 4 towns and acknowledgment of mature base in metros may lead to a transition period. At the same time, competiti...
Reduce Dr Lal Pathlabs Ltd For Target Rs.2,500 - Yes Securities
Reduce Dr Lal Pathlabs Ltd For Target Rs.2,500 - Yes Securities
Source: Yes Securities Ltd
2023-11-26 09:48:50 am
Buy Dr Lal Pathlabs Ltd For Target Rs.2,575 - JM Financial Robust execution with strong margin delivery DLPL reported 14.4% core revenue growth with better-than-expected EBITDAM of 29.6% (3 ppt beat), thereby driving 20% PAT beat. Price hikes, lower consumption cost, better portfolio mix and operating leverage aided margins. Typically, 2Q is a strong quarter (not representative) and 2H weaker. Volume recovered sequentially, as expected, aided by the fever and dengue season. DLPL is focusing on widening and deepening its presence in uncovered marke...
Buy Dr Lal Pathlabs Ltd For Target Rs.2,575 - JM Financial
Buy Dr Lal Pathlabs Ltd For Target Rs.2,575 - JM Financial
Source: JM Financial Institutional Securities Ltd
2023-11-10 02:58:36 pm